Last updated on October 2019

COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention


Brief description of study

The primary purpose of this study is to determine whether treatment with the Cobra PzF stent with 14 day Dual Anti-Platelet Therapy (DAPT) has a better safety profile compared to standard FDA approved Drug Eluting Stent plus 6-Month Dual Anti-Platelet Therapy in patients undergoing coronary intervention who also require oral anticoagulation.

 

Clinical Study Identifier: TX209900

Find a site near you

Start Over

Office of Clinical Research

1981 Marcus Avenue Suite E110 Lake Success, NY USA
  Connect »